NEW YORK (TheStreet) -- Biogen Idec
(BIIB) shares are down -1.5% to $301.50 in trading on Wednesday, following the release of the company's first quarter earnings report.
Year over year quarterly revenue rose 50.5% to $2.13 billion, beating analysts consensus estimates of $2 billion.
Must Read: Warren Buffett's 10 Favorite Stocks
SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.
However, earnings per share for the biotech company missed guidance, posting an EPS of $2.47, missing analysts estimates by 9 cents.
Biotech ETF stocks are takings hits across the board as Reneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Amgen (AMGN) and Celgene (CELG) are all declining in trade today.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts